Valuations make buyers out of biotechs once seen as takeover targets

05/10/2013 | Reuters

Rising stock valuations due to promising drug data have transformed biotech drugmakers from acquisition targets into potential buyers, analysts said. Aside from rich valuations, easy access to financing and low interest rates provided alternatives to funding research and commercialization, a health banker said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care